STATegics, Inc. Announces a Grant Supporting the Company’s Program in Acute Kidney Injury
STATegics, Inc. announced today that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has awarded the company a grant to advance its proprietary erythropoietin receptor agonist compounds for the treatment of acute kidney injury (AKI).
MENLO PARK, Calif. - Aug. 15, 2013 - PRLog -- STATegics, Inc. announced today that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has awarded the company a grant of $227,624 to advance its proprietary erythropoietin (EPO) receptor agonist compounds for the treatment of acute kidney injury (AKI). The award will fund the characterization of the company’s compounds in key preclinical studies supporting their further development for the treatment of AKI.
“We have made significant progress in the discovery and development of broadly protective, non-erythropoietic EPO receptor agonist compounds. Our recent results illustrate the potent effects of STATegics’ compounds in protecting kidney cells from cellular damage both in vitro and in vivo. This new grant allows for more detailed characterization of these protective effects in preclinical models of acute kidney injury, and we look forward to continued advancement of the compounds toward clinical trials,” stated Juha Punnonen, MD, PhD, Chief Executive Officer of STATegics.
About AKI and small molecule EPO receptor agonists
AKI leads to the sudden loss of kidney function and presents a significant complication associated with 5-7% of hospital admissions and approximately 30% of patients admitted to intensive care units. Common causes of AKI include major vascular surgery, inflammatory disease, myocardial infarction, sepsis, diagnostic imaging contrast-agents and aminoglycoside antibiotics.
About STATegics, Inc.
STATegics, Inc. is a privately-held biopharmaceutical company in Menlo Park, CA, committed to the discovery and development of small molecule modulators of cytokine receptors. The company’s lead programs are focused on small molecule agonists of erythropoietin and thrombopoietin receptors for the treatment of central nervous system diseases, organ protection and thrombocytopenia.
Contact: Juha Punnonen, CEO, STATegics, Inc.: juha.punnonen@